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ADAMTS Proteases: Potential 
Biomarkers and Novel Therapeutic 
Targets for Cartilage Health
Sinan Kandir
Abstract
The equine locomotor system’s health plays a key role on athletic performance. 
Bone and joint diseases are the major causes of lameness. Poor performance and 
diseases lead to great economic loss to equestrian sports and horse breeders. 
Therefore, prevention, early diagnosis, and therapy of joint diseases are important. 
A disintegrin-like and metalloproteinase with thrombospondin motifs (ADAMTS) 
proteinase family plays an important role in many physiological processes such 
as tissue reorganization, coagulation, and angiogenesis. Aggrecan proteinases 
ADAMTS-4 and ADAMTS-5 are physiologically responsible for the restructuring 
with enzymatic cleavage of the cartilage, specific biomarkers in the synovium or 
body fluids for early diagnosis, and potential specific therapeutic targets in order 
to their role on degenerative joint diseases physiopathology in humans and various 
animals.
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1. Introduction
A disintegrin-like and metalloproteinase with thrombospondin motifs 
(ADAMTS) protease family plays an important role in many physiological and 
physiopathological processes. The ADAMTS family is an important potential 
biomarker for the evaluation of early diagnosis due to its roles in the physiopatho-
logical mechanisms of many diseases such as cancer, arthritis, and atherosclerosis. 
ADAMTS-4 and ADAMTS-5 have been reported to play an important role in the 
pathogenesis of osteoarthritis in humans and various animals, following their first 
molecular purification and cloning.
Articular cartilage is structurally composed of partially chondrocyte cells and a 
large number of extracellular matrix components. Many macromolecules have been 
identified in cartilage tissue, including collagen fibrils, aggregate proteoglycans, 
and glycoproteins. Although joint damage is caused by oxidative metabolism-
induced free radicals and hypoxic conditions, the main reason is the increase in 
proteolytic enzymes. Matrix metalloproteinases (MMPs), pro- and anti-inflam-
matory cytokines interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), 
and retinoic acid are the main biomarkers recommended for the diagnosis of joint 
damage [1–8].
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In this chapter, we focus on ADAMTS proteases and their role on cartilage health 
for joints’ stability, their possible usage as damage biomarkers for early diagnosis, 
and novel therapeutic properties.
2. ADAMTS proteases
Metzincins are a superfamily of zinc-dependent metalloproteases, metallopro-
teinases, or metalloendopeptidases, which are responsible for many physiological 
functions that also include cartilage turnover due to their regulatory activities on the 
extracellular matrix (ECM). The metzincins constitute by the zinc-binding catalytic 
motif consensus sequence HEXXHXXGXX (H/D) exactly; the binding of a zinc mol-
ecule is modulated by the three histidines (or an aspartic acid in the third position), 
the acid-base catalysis is facilitated by the glutamic acid residue in general, and the 
steric flexibility is acquired by the small glycine residue in the catalytic motif [9].
The first referenced equine gene mapping project was initiated in October 1995 
by the “First International Equine Gene Mapping Workshop,” in order to search 
answers of the main questions “speed gene” and “evidence of heritable trait”, and the 
first construction of a low density, male linkage map in 1999 was reported [10, 11]. 
Thereafter, the first domestic horse gene map (EquCab2.0), a thoroughbred mare 
Twilight’s gene sequence, was released in 2007 and published in November 2009 
[12–16]. The latest version of high-quality equine gene map EquCab3.0 is available 
and enables to detailed data about genes and encoding proteins [16]. The Vertebrate 
Gene Nomenclature Committee (VGNC) [17] has standardized names to genes in 
vertebrate species including horse [18, 19]. According to these accessible latest data 
versions, the equine ADAMTS and ADAMTS-like family members with chromo-
somal locations are listed in Table 1.
2.1 ADAMTS family
Towards the end of 1990s, Kuno et al. [20] described a new family of metallo-
proteinase, which consists of sequence similarity with snake venom disintegrin that 
was upregulated in colon adenocarcinoma cell line as a specific gene for cachexi-
genic tumor and was named a disintegrin-like and metalloproteinase with throm-
bospondin type-1 motif (ADAMTS). The equine ADAMTS and ADAMTS-like 
proteins are a superfamily comprised of 19 and 7 members, respectively (Table 1). 
The ADAMTSs are secreted proteinases and multidomain enzymes constituted 
of zinc-binding active site motif similar to adamalysin (ADAMs) and ensued by a 
metalloproteinase domain with that of reprolysins (snake venom metalloprotein-
ases) and disintegrin-like domain (Figures 1 and 3). ADAMTS-like (ADAMTSL) 
family and papilin are newly identified and secreted ECM-related proteins which 
are relatives to ADAMTS proteases. Additionally, they lack catalytic activity due 
to the absence of prometalloprotease and the disintegrin-like domain which are 
found in the ADAMTSs [21–24]. ADAMTSs differ from ADAMs with the lack of a 
transmembrane domain and the inclusion of well-conserved thrombospondin 1-like 
repeats, a cysteine-rich domain, and the CUB (complement subcomponents C1s/
C1r, Uegf, BMP1) domain, thus being soluble extracellular proteases [25–31].
The main physiological functions of equine ADAMTSLs and papilin are 
extensively unknown; thus they have some troubles and need to further detailed 
investigations. However, recent studies on genome-wide association analysis and 
transgenic animals have indicated that ADAMTS, ADAMTSL, and papilin gene 
mutations cause lethal embryonic defects and autosomal recessive Mendelian 
disorders such as human Ehlers-Danlos syndrome [32], bovine dermatosparaxis 
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[33, 34], human Weill-Marchesani syndrome [35], canine ectopia lentis [36], 
human Geleophysic dysplasia [37], canine Musladin-Lueke syndrome [38], and 
thrombotic thrombocytopenic purpura [39]. In consideration of this knowledge, 
ADAMTSs, ADAMTSLs, and papilin could be responsible as most commonly 
screened genetic disorders among horses as early embryonic death and abnormali-
ties, junctional epidermolysis bullosa [40], hereditary equine regional dermal 
asthenia [41], thrombocytopenia and, von Willebrand disease [42].
Gene/protein 
name
Chromosomal 
Location
VGNC_
ID
ENSEMBL UniProt
ADAMTS1 26 15061 ENSECAG00000016339 F6YLN3
ADAMTS2 14 55397 ENSECAG00000016328 F6X633
ADAMTS3 3 — ENSECAG00000019061 F6ZC90/F7A3A4
ADAMTS4 5 15070 ENSECAG00000024172 F6YRD3/
A0A3Q2H7G6
ADAMTS5 26 59233 ENSECAG00000006500 F7ACI3/
A0A5F5PZN1
ADAMTS6 21 15071 ENSECAG00000029347 F6X9L7
ADAMTS7 1 15072 ENSECAG00000007527 F6W0M1
ADAMTS8 7 15073 ENSECAG00000014164 F6ZXN7
ADAMTS9 16 15074 ENSECAG00000019880 F6VTC7
ADAMTS10 7 55772 ENSECAG00000016210 F6QIB9
ADAMTS12 21 15062 ENSECAG00000016121 F6TW13
ADAMTS13 25 — (NCBI Gene ID: 100069281) —
ADAMTS14 1 15063 ENSECAG00000014713 F7D1G5
ADAMTS15 7 15064 ENSECAG00000015715 F6V0J9
ADAMTS16 21 15065 ENSECAG00000000787 F6W504
ADAMTS17 1 15066 ENSECAG00000000579 F7DNJ9
ADAMTS18 3 15067 ENSECAG00000019006 F7A7V7
ADAMTS19 14 15068 ENSECAG00000023694 F6YNK0
ADAMTS20 6 15069 ENSECAG00000020835 F6PZV0
ADAMTSL1 
(Punctin-1)
23 15075 ENSECAG00000015972 F6W1K7
ADAMTSL2 25 15076 ENSECAG00000011887 F6TEW7
ADAMTSL3 
(Punctin-2/
SH3GL3)
1 22941 ENSECAG00000012008 F6T6C4
ADAMTSL4 5 15077 ENSECAG00000019154 F7A7L3
ADAMTSL5 7 50328 ENSECAG00000009642 F6X928
ADAMTSL6 
(THSD4)
1 51434 ENSECAG00000022944 F6UWV1
PAPLN 
(Papilin)
24 21150 ENSECAT00000008176 F6VT48
Table 1. 
The equine ADAMTS and ADAMTS-like family members with chromosomal locations and accession numbers.
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3. Role of ADAMTS family on equine cartilage health
Musculoskeletal system health is crucial for equine locomotion. This system is 
responsible to deploy the mechanical energy to the joints for efficient movement 
and specific biomechanical functions. There are many types of joints presented, 
where a majority of the free movements are managed by diarthrodial or synovial 
joints in the body. Cartilage tissue, which is the most important part of the diarthro-
dial joints, is absorbed and the loading energy throughout locomotion is distrib-
uted. Alterations due to inaccurately loading or metabolic disruptions could lead 
to acute or chronic damage, namely as arthritis, osteoarthrosis, or osteoarthritis 
to the joint and its critical component cartilage tissue, and restrict the locomotor 
functions. It is important to understand the molecular mechanisms of healthy and 
damaged cartilage tissues by the novel candidate molecular biomarkers in order to 
Figure 1. 
Phylogenetic analysis of equine ADAMTS protein family. The evolutionary history was inferred using the 
maximum parsimony method. The most parsimonious tree with length = 9505 is shown. The consistency index 
is (0.751174), the retention index is (0.551189), and the composite index is 0.440603 (0.414039) for all sites and 
parsimony-informative sites. The percentage of replicate trees in which the associated taxa clustered together 
in the bootstrap test (500 replicates) is shown next to the branches [43]. The MP tree was obtained using the 
subtree-pruning-regrafting (SPR) algorithm (p. 126 in Ref. [44]) with search level 1 in which the initial trees 
were obtained by the random addition of sequences (10 replicates). Branch lengths were calculated using the 
average pathway method (see p. 132 in Ref. [2]) and are in the units of the number of changes over the whole 
sequence. They are shown next to the branches. This analysis involved 19 amino acid sequences. There were a 
total of 2768 positions in the final dataset. Evolutionary analyses were conducted in MEGA X [45].
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early detection, easily clinical application, and therapy. Hence, we will focus on the 
cartilage health and importance of the ADAMTS family in this section.
3.1 Healthy cartilage tissue
Cartilages are divided into three major types as histological and biochemical 
properties in the body as hyaline, elastic and fibrocartilage. The distinctive features 
among these cartilage types are water content/dry matter balance and fiber types. In 
the diarthrodial joints, hyaline cartilage is existed on the articular surfaces and is well 
resist to pressure stress during various locomotion by its unique structure [46, 47].
Avascularized, unnerved, alymphatic hyaline cartilage (Latin words “hyălĭnus” 
meaning “glassy; made of glass; transparent”) tissue’s matrix is fundamentally 
constituted by water (%63–70), collagens (the majority type II in normal hyaline 
cartilage), non-collagenous proteins, and proteoglycans (the majority of aggre-
cans), while the most compounds are glycosaminoglycans (GAG) [48, 49].
Proteoglycans are classified into four subgroups related to their function: 
intracellular, cell-surface, pericellular, and extracellular. In the cartilage tissue, 
hyaluronan- and lectin-binding proteoglycans (hyalectans; aggrecan, versican, 
neurocan, and brevican) and small leucine-rich proteoglycans exist. Hyalectans are 
compromised with a similar structure in their tridomain structure; the N-terminal 
domain binds to hyaluronan, a central domain with the core protein for attachment 
of GAG chains, and the C-terminal region that binds lectins [50, 51].
The major proteoglycans in the diarthrodial joints aggrecans are the crucial 
elements for the biomechanical function with well-balanced load distribution and 
transmissions in order to provide the viscoelastic properties, the tight junctions, 
and the bridges of the extracellular matrix (ECM) [50, 52–55]. Aggrecans have 
a large molecular mass that contains GAG side chains comprising of the mostly 
chondroitin sulfate and keratan sulfate. They have three globular domains (G1, G2, 
and G3) to maintain the stabilization of protein complexes and to ensure mechani-
cal features of cartilage. These highly conserved globular domains among the 
vertebrates have specific cleavage sites for proteases such as ADAMTSs (Figure 2) 
[50, 55–57]. The GAG’s chondroitin sulfate and keratan sulfate contents of aggrecan 
could directly affect the aggrecanase activity by ADAMTSs [58].
Although, the hyaline cartilage consists of the chondrocytes which are the 
only cell type; this cell population has shown different morphological properties 
under the microscope and has been identified as dark, light, and adipocyte-like 
Figure 2. 
Schematic view of aggrecan proteoglycan [50, 55, 56].
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(adipochondrocytes) [59]. Chondrocytes manage the functional regulation of joint. 
These cell groups provide the synthesis and degradation of the ECM compnents, 
to support growth and regeneration, through the maintenance the gene expression 
and metabolism responded by mechanical stimuli. Extracellular matrix and proteo-
glycans are expressed by chondrocytes in articular joints [60–64].
The interleukins (ILs) and tumor necrosis factor α (TNF-α) cytokines are syn-
thesized by chondrocytes, synovium, or inflammatory cells [7, 65]. Proteoglycan 
depletion has been stimulating physiopathologic processes, which is the main 
cause of degenerative joint diseases, e.g., osteoarthritis [66, 67]. Interleukins and 
TNF-α exert their effects on many diseases nonselectively from dental to cancer 
[68, 69], despite that a biomarker must be tissue-specific [70, 71]. Thus, in the last 
decade, the equine orthopedic researches have been deeply focused on proteogly-
cans, especially aggrecanases.
3.2 Aggrecanases on cartilage physiopathology
As it is well known, the proteases are responsible for proteolysis processes, 
which are catalytic enzymes to breakdown of the proteins into small polypeptides 
and amino acids by cleaved peptide bonds. The metalloproteinase superfamily 
members show their proteinase activity on osteoarthritis formation throughout 
the physiopathological processes. The matrix metalloproteinases (MMPs) and 
their endogenous inhibitors tissue inhibitors of metalloproteinases (TIMPs) are 
extensively studied; besides this, recent advances have indicated that the role of 
ADAMTS proteinase family is more considerable due to its abundant and specific 
aggrecanase activity by ADAMTS-4 and -5.
The aggrecan residues which cleaved at the glutamate 373-alanine 374 bond 
between the G1 and G2 interglobular domains were found at the synovial fluid 
analysis from various joint diseases (inflammatory or noninflammatory) in humans 
[72]. The first aggrecanase was purified and cloned by Tortorella et.al and named 
as aggrecanase-1 (currently termed as ADAMTS-4). They showed that ADAMTS-4 
cleaves the aggrecan at the glutamic acid-373-alanine-374 bond [73]. After a while, 
Abbaszade et al. described aggrecanase-2 and named ADAMTS-11 (presently 
known as ADAMTS-5) [74]. ADAMTS-4 and ADAMTS-5 cleave the aggrecan at five 
common aggrecanase specific sites (Glu373-Ala374, Glu1480-Gly1481, Glu1667-
Gly1668, Glu1771-Ala1772, and Glu1871-Leu1872,); nonetheless, ADAMTS-5 
cleaves an additional site (Glu1480-Gly1481). Moreover, ADAMTS-5 is approxi-
mately twice slower than ADAMTS-4 [75, 76].
ADAMTS-4 and -5 are distributed in equine hoof lamina [78] and joints [79] 
and are expressed more in cartilage tissue than other tissues [80]. In our study, 
we observed concour horses after 50 minutes of a regular exercise program. As a 
result the serum ADAMTS-5 levels significantly increased but ADAMTS-4 did not. 
We concluded that ADAMTS-4 and ADAMTS-5 are using different pathways to 
physiologic and physiopathologic response [81]. Additionally and interestingly, the 
owners, whose horses had higher individual ADAMTS-5 serum levels, called the 
local veterinarians to complain about an orthopedic problem two or three weeks 
after our observations (unpublished data).
ADAMTS-4 needs to interact with sulfated GAGs that are attached to aggrecan 
core protein in order to effectively aggrecan degradation [58, 82]. ADAMTS-4 
lacks the thrombospondin repeat domain on C-terminal region (Figure 3). This 
unique configuration allows bind to the adhesive glycoprotein fibronectin [82, 83]. 
Fibronectin is a glycoprotein that is found in low levels under physiologic condi-
tions at the articular surface of cartilage and increases on pathologic conditions by 
activating innate immune response with toll-like receptors that are responded to 
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regulate the innate immune system in case of pathogen-related inflammation [84, 
85]. Hashimoto et al. reported that fibronectin is a novel inhibitor of ADAMTS4 
activity in addition to its original endogenous inhibitor TIMP-3. Hence, fibronec-
tin could be a potent preventive therapeutic against aggrecan degradation related 
to degenerative joint diseases [82]. While ADAMTS-4 is mediated by TNF-α, 
IL-1β, and nuclear factor-kappa B (NFκB) released from synovial macrophages, 
the regulation of ADAMTS-5 is not totally but predominantly independent of the 
these cytokine response [86].
4. Conclusion
The differences between synthesis pathways of ADAMTS-4 and ADAMTS-5 
have to be taken into consideration on the TNF-α and IL-1 neutralization-targeted 
cytokine inhibitor therapies throughout degenerative joint diseases. In addition to 
classical therapy strategies, novel gene therapies are arising nowadays. An exciting 
work on this subject is a knockout murine model by the correction of ADAMTS-13 
gene, which causes von Willebrand disease and leads to thrombotic thrombocy-
topenic purpura [87]. Transgenic animal studies with ADAMTS-4 and -5 double 
knockout mice [88, 89] revealed that aggrecan deletion protects from progressive 
osteoarthritis. These results have indicated that ADAMTS-4 and -5 may be potent 
therapeutic agents against laminitis and osteoarthritis, tendon, and ligament 
injuries for equine gene therapy.
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Figure 3. 
Domain organization of ADAMTS aggrecanases. SP: signal peptide; T: thrombospondin type 1 motif; and 
CYS: cysteine [77].
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